Protalix BioTherapeutics
PLX
47 hedge funds and large institutions have $159M invested in Protalix BioTherapeutics in 2013 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 7 closing their positions.
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more capital invested
Capital invested by funds: $156M → $159M (+$2.69M)
0.35% more ownership
Funds ownership: 3.41% → 3.75% (+0.35%)
0% more funds holding
Funds holding: 47 → 47 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
95% less call options, than puts
Call options by funds: $210K | Put options by funds: $3.84M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$3.94M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
+$2.84M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$1.61M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.59M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MNA
Manning & Napier Advisors
Fairport,
New York
|
-$784K |
| 2 |
OAM
Oberweis Asset Management
Lisle,
Illinois
|
-$286K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$268K |
| 4 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
-$257K |
| 5 |
Morgan Stanley
New York
|
-$233K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SGAM
51
Smith Group Asset Management
Dallas,
Texas
| – | -$23K | -459 | Closed |
|
52
Barclays
London,
United Kingdom
| – | -$719 | -14 | -70% |
|
53
AllianceBernstein
Nashville,
Tennessee
| – | +$462 | +9 | New |
|
PLX Hedge Fund Activity: Q3 2013 in Review
47 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q3 2013, worth a combined $159M — up 1.7% from $156M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PLX positions and 7 closed out — a net gain of 1 holder — while 21 added to existing stakes and 11 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $3.94M. The largest seller was Manning & Napier Advisors, exiting entirely with an estimated $784K sold.
- 47 institutional investors held Protalix BioTherapeutics (PLX) as of Q3 2013, unchanged from Q2 2013.
- Funds reported $159M of Protalix BioTherapeutics stock for Q3 2013, up 1.7% quarter-over-quarter.
- 8 funds opened new Protalix BioTherapeutics positions in Q3 2013 and 7 closed out, a net change of +1 holder.
- The largest Protalix BioTherapeutics buyer in Q3 2013 was Baillie Gifford & Co, an estimated $3.94M added.
- The largest Protalix BioTherapeutics seller in Q3 2013 was Manning & Napier Advisors, an estimated $784K sold.
Based on aggregated 13F filings for Q3 2013.